Chris Spencer Director / Addiction Specialist
30th Sept, 2026
Review by: Chris Spencer, Addiction Specialist

Drug-Related Increases and Fatalities in Europe Over the Last Five Years

- Rehab treatment centre in Marbella, Spain

The evidence does not support one simple conclusion that every form of drug use and every drug-related fatality has risen uniformly across Europe over the last five years. Patterns vary by substance, country, age group and how deaths are recorded. However, the broader picture is concerning: drug availability remains high, cocaine-related harms are becoming more prominent, opioids continue to drive many fatal overdoses, and new synthetic opioids are adding risk to an increasingly unpredictable market.

For people searching for a “drugs related increase over the last 5 years”, the most accurate answer is that Europe is experiencing a changing rather than uniform drug crisis. Some substances and harms are rising sharply, while mortality figures can fluctuate from year to year and are affected by differences in reporting systems.

Drug availability in Europe remains high

The European Union Drugs Agency (EUDA) reports that illicit drug availability remains high across Europe. Supply data do not measure drug use directly, but they can indicate the scale and resilience of the market.

Between 2014 and 2024, the quantity of cocaine seized in EU Member States rose by 471%, while methamphetamine rose by 1,019%, MDMA by 386%, amphetamine by 150% and herbal cannabis by 79%.
Drug-Related Increases and Fatalities in Europe: Five-Year Trends - Addiction Treatment Centre
These are ten-year rather than five-year comparisons, but they provide important context for the more recent trend: Europe has entered the last five years with a broad and increasingly diverse drug supply.

Cocaine is now Europe’s second most commonly used illicit drug after cannabis. EUDA survey estimates indicate that 2.5 million people aged 15 to 34 used cocaine in the previous year. Of 14 European countries with comparable surveys conducted since 2023, seven reported higher estimates than in their previous survey.

Wastewater monitoring also indicates that cocaine use has become more geographically widespread in many European cities. This does not mean every individual is using more cocaine, but it does suggest that the drug is accessible across a wider range of communities than in the past.

Cocaine-related harm is a growing concern

Cocaine’s growing availability has consequences beyond occasional recreational use. The EUDA identifies cocaine as the most frequently reported substance in acute drug-toxicity presentations at its sentinel hospital emergency departments. It was involved in 27% of drug-induced deaths in the latest data from reporting European countries.

Cocaine can increase heart rate and blood pressure and may contribute to cardiovascular emergencies, particularly with heavy or repeated use. The risk can rise when cocaine is combined with alcohol. The body produces cocaethylene when the two are used together, which may increase health risks.

In 2024, cocaine was involved in the majority of reported overdose deaths in Spain, Cyprus, Luxembourg, Malta and Portugal. This should not be interpreted to mean cocaine alone caused every death. Drug fatalities frequently involve multiple substances, and toxicology findings do not always establish a single cause.

Opioids remain central to fatal overdoses

Opioids, including heroin, prescription opioids and synthetic opioids, continue to be involved in a large proportion of fatal overdoses across Europe. The EUDA estimated that approximately 7,600 deaths involving one or more illicit drugs occurred in the EU in 2024.

The total was slightly lower than the 7,653 deaths reported for 2023, so it would be inaccurate to describe EU overdose fatalities as rising every year. However, the number remains very high, and the pattern has changed among some groups. The number of reported overdose deaths among people aged 50 to 64 more than doubled overall between 2014 and 2024. This reflects the health needs of an ageing population of people with long-term drug dependence.

Most fatal overdoses involve more than one substance. Combining opioids with alcohol, benzodiazepines or other sedatives can increase the risk of respiratory depression, unconsciousness and death. The presence of a substance in toxicology does not automatically prove it was the sole cause of death, but it remains important evidence for prevention and treatment planning.

Fentanyl, nitazenes and an unpredictable synthetic-opioid market

The North American fentanyl crisis should not be treated as a direct description of Europe. European drug markets and mortality patterns are different, and heroin remains more prominent in many countries. Nevertheless, potent synthetic opioids are an increasing concern.

EU data from 15 Member States linked fentanyl and fentanyl derivatives to 208 deaths in 2024, up from 129 in 2023. This is a substantial year-on-year rise, though it remains a smaller part of Europe’s overdose picture than in the United States.

Nitazenes are another group of highly potent synthetic opioids requiring close monitoring. In England and Wales, 195 deaths registered in 2024 involved nitazenes, almost four times the 52 registered in 2023. These figures refer to registrations rather than necessarily the year of death, due to inquest delays.

UK trends: rising registrations and changing substances

UK figures must be considered separately from EU statistics. In England and Wales, 5,565 drug-poisoning deaths were registered in 2024, the highest number since records began in 1993. This was 2.1% higher than the 5,448 registrations in 2023.

However, registration data must not be confused with occurrence data. Only 37.2% of deaths registered in 2024 occurred during that year; many were registered after a coroner’s inquest. Finalised occurrence figures show 4,798 drug-poisoning deaths in 2019 and 4,849 in 2023. The five-year trend in actual deaths is therefore more complex than registration figures alone suggest.

Cocaine-related deaths in England and Wales have risen more clearly. There were 1,279 registered deaths involving cocaine in 2024, 14.4% higher than in 2023 and more than eleven times the 2011 total. Opioids still accounted for almost half of all registered drug-poisoning deaths in 2024.

Ketamine and polysubstance use

Ketamine is not a major driver of fatal overdose in the way that opioids are, but its availability and related harms are becoming more visible in Europe. The EUDA reports wider availability, increasing detection in wastewater and risks including bladder damage, mental-health problems and cardiovascular effects with intensive use.

Ketamine is frequently used with other drugs or alcohol. This wider pattern of polysubstance use makes individual risk harder to predict and complicates emergency care and addiction treatment. Someone may need help not only for one drug, but for a combination of cocaine, alcohol, cannabis, ketamine, prescription medicines or opioids.

EUROPE’S RISING DRUG-RELATED RISKS

Speak to us today for a confidential, no-obligation conversation

Treatment can address drug use before it becomes a crisis

A rise in availability or drug-related deaths does not mean that recovery is out of reach. Early assessment can identify dependence, co-occurring anxiety, depression, trauma, physical-health issues and the practical pressures that make drug use difficult to stop.

At our private residential addiction treatment centre in Marbella, Spain, Phoenix Programmes provides structured support for people struggling with drug dependence and polysubstance use. For people travelling from the UK, residential rehab in Marbella can offer distance from familiar routines, social pressures and triggers while they focus on treatment.

Detoxification may be appropriate for some substances, particularly where opioid, alcohol or sedative dependence is present, but it should be clinically assessed. Detox alone does not address the underlying factors that contribute to relapse. A wider treatment plan may include medical assessment, psychological therapy, relapse prevention, support for mental health and aftercare planning.

Frequently Asked Questions

Have drug deaths increased across Europe in the last five years?
Not consistently in every country or for every substance. The EU recorded around 7,600 illicit-drug-related deaths in 2024, slightly below the 2023 estimate. However, cocaine harms, potent synthetic opioids and age-related overdose risks remain serious concerns.
Is cocaine use increasing in Europe?
Evidence from wastewater monitoring, seizures and some national surveys suggests cocaine has become more widely available and is affecting a broader range of communities. It is also prominent in emergency presentations and specialist treatment demand.
Is fentanyl a major problem in Europe?
Fentanyl is a concern, particularly because of its potency, but Europe’s drug market differs from North America’s. Heroin and other opioids remain more widely implicated in overdose deaths overall. Nitazenes are also an emerging European concern.
When should someone seek professional treatment for drug use?
A professional assessment is appropriate when drug use becomes difficult to control, causes health, financial or relationship problems, involves several substances, leads to overdose or emergency care, or continues despite clear harm.

Speak to an addiction treatment team

If you or someone close to you is affected by cocaine, opioids, ketamine, prescription drugs or multiple substances, a confidential assessment can clarify what support may be appropriate. Phoenix Programmes in Marbella can discuss whether private residential addiction treatment in Spain is a suitable next step.
If you think that you or someone you love might have a problem with drug or alcohol addiction, compulsive behaviour or emotional disorders, reach out and speak to our specialist addiction rehab treatment team on our confidential helpline +34 691 881 422. Immediate admission available.

Working Hours

Address

Follow Us

Individual Treatment in Spain

Individual Treatment in Spain

Treatment at Your Residence

Exclusive Individual Treatment Programme at Your Residence